Addleshaw Goddard advises Phoenix Equity Partners on strategic investment in FutureMeds
Addleshaw Goddard has advised long-standing client Phoenix Equity Partners on its strategic investment into FutureMeds, Europe’s leading independent clinical trial site network.
FutureMeds provides patient recruitment and clinical trial management services across Europe, currently operating 28 clinical sites in 7 countries with hybrid and virtual solutions in 18. The investment by Phoenix will support FutureMeds’ ambitious growth plans, enabling further expansion of its European footprint and service capabilities across therapeutic areas.
The cross-border Addleshaw Goddard team was led by Paul Medlicott and George Danczak, coordinating efforts across the UK, Poland, Spain, and Germany. Core team members included:
- UK – Corporate: Miriam Doukhan, Sylwia Karkusiewicz, Tom Wookey, Ethan Turner; Tax: Zoe Fatchen, Cat Concannon; Banking: Ewen Scott, Cat Killeen, Nick Lewin
- Poland – Corporate: Magda Szewczyk, Lukasz Czerepak
- Spain – Corporate: Gonzalo Fernandez, Cesar Bascones
- Germany – Corporate: Hubertus Schroeder, Fabian Neppessen
The firm also oversaw coordination with local counsel Kinstellar in Bulgaria and Ukraine.
Paul Medlicott, Corporate Partner at Addleshaw Goddard, commented:
